In the BioHarmony Drug Report Database
Aminolevulinic acid
Ameluz, Gleolan, Levulan, Gliolan (aminolevulinic acid) is a small molecule pharmaceutical. Aminolevulinic acid was first approved as Ameluz on 1999-12-03. It is used to treat actinic keratosis in the USA. It has been approved in Europe to treat actinic keratosis, basal cell carcinoma, and glioma. Levulan kerastick’s patent is valid until 2038-01-12 (FDA).
Trade Name
|
Ameluz, Gliolan |
|---|---|
Common Name
|
aminolevulinic acid |
ChEMBL ID
|
CHEMBL601 |
Indication
|
actinic keratosis, basal cell carcinoma, glioma |
Drug Class
|
Image (chem structure or protein)